Interleukin-2 Inc. name change
Alexandria, Va.-based R&D venture to go by name of Cel-Sci Corp. effective the first week of March following a shareholder vote Feb. 23. Depending on FDA's requirements, Phase I or Phase II studies of natural IL-2 involving 35 patients with advanced malignant melanoma will begin soon at the Melanoma Treatment Center, University of South Florida, College of Medicine. Results of Phase I/Phase II trials of IL-2 with 25 patients at St. Thomas' Hospital Medical School, London, England showed that the patients had an increase in lymphnode size and activity, which resulted in a reduction in tumor size.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.